P-21 and Cerebrolysin: Exploring Their Research Evidence
P-21, also called P021 in research papers, has been studied mainly in preclinical models. Research has examined its molecular, cellular, and behavioral effects in experimental settings.
Cerebrolysin provides a useful comparison because its research base includes experimental studies and human clinical research. This article focuses on P-21 research and explains how its evidence base differs from Cerebrolysin.
What Is P021 in Experimental Research?
P021 is a small synthetic peptide based on a biologically active part of ciliary neurotrophic factor (CNTF). Researchers developed it from a CNTF derived sequence. The compound is identified as Ac-DGGLAG-NH₂ in the research literature. P021 was developed as a peptide mimetic for experimental research into CNTF related activity.
Research on P021 has focused on its biological activity in laboratory and animal studies. The compound has not been established through human clinical research. Its current research base therefore remains preclinical with findings coming from experimental studies rather than approved human use.
Which Experimental Models Have Been Used to Study P021?
P021 research has used several animal models, including aged Fisher rats, 3xTg-AD transgenic mice, and Ts65Dn mice. Studies have also included wild-type mice as comparison animals. The 3xTg-AD model has been used for Alzheimer-like research, while aged Fisher rats have been used to study age-related changes.
Researchers have also tested P021 in SH-CDKL5-KO cells and Cdkl5 knockout mice. These models were used to study CDKL5 deficiency. Other work has continued to use 3xTg-AD mice. Overall, the research includes both cell-based models and animal models.
What Molecular Measures Have Been Studied in P021 Research?
P021 research has measured BDNF and GSK3β in animal models. Studies found that P021 increased BDNF expression in the brain. Researchers also measured GSK3β activity and its inhibitory phosphorylation at Ser9. In 3xTg-AD mice, P021 increased the pGSK3β/GSK3β ratio, which indicates lower GSK3β activity.
The findings also link these two measures in the same research pathway. Higher BDNF expression was associated with increased inhibitory phosphorylation of GSK3β. Researchers therefore examined BDNF expression together with GSK3β activity to study how P021 affected this signaling pathway in the experimental models.
What Have P021 Studies Measured in Relation to Tau?
Researchers have measured total tau, human tau, and phosphorylated tau in P021 studies. In 3xTg-AD mice, researchers examined tau phosphorylation at the AT8 and PHF1 sites. They also measured tau levels through Western blot analysis and examined PHF1 staining in the hippocampus.
The studies reported lower tau hyperphosphorylation and tau accumulation after P021 treatment. These changes were measured at major sites linked with neurofibrillary tau pathology. Researchers also examined tau distribution in retinal tissue in aged rats and 3xTg-AD mice including total and phosphorylated tau.
What Have Researchers Measured in Relation to Amyloid-β?
P021 studies have examined soluble Aβ1–40 and Aβ1–42, along with insoluble forms. In 3xTg-AD mice, P021 was linked to a significant reduction in soluble Aβ in one treatment period. No significant change was found in insoluble Aβ. Researchers also examined Aβ plaque load in the hippocampus, including the CA1 and subiculum regions.
Other work examined Aβ pathology through immunohistochemical staining, Western blot analysis, and thioflavin-S staining. These measurements included Aβ-positive area, plaque area, and amyloid-related protein changes. Experimental P021 exposure was associated with differences in Aβ plaque measurements in the tested 3xTg-AD mice.
How Have Neurogenesis and Synaptic Measures Been Studied?
P021 studies have assessed neurogenesis by counting Ki-67-positive and doublecortin-positive cells in the hippocampal dentate gyrus. Ki-67 was used as a marker of cell proliferation, while doublecortin marked immature neurons. Researchers also examined MAP2, a dendritic marker, to assess dendritic structure.
Synaptic changes have been studied through markers such as synaptophysin and PSD-95. Other work measured NR1, NR2A, NR2B, GluR1, GluR2/3, CREB, and phosphorylated CREB. These measures were used to examine synaptic density and synaptic plasticity following experimental P021 exposure.
What Have Behavioural Tests Added to P021 Research?
P021 behavioral research has mainly examined learning, memory, and anxiety-related behavior. In 3xTg-AD mice, studies used the novel object recognition test and Morris water maze. The novel object test measured recognition memory through preference for a new object. The water maze assessed spatial learning and memory through measures such as escape latency, time to enter the target area, and time spent in the target quadrant.
Researchers also used the elevated plus maze to examine anxiety-related behavior. Another P021 study used novel object recognition to assess episodic memory after long-term treatment. These tests provided behavioral measures that could be compared between P021-treated and control animals within the same experimental models.
What Has More Recent P021 Research Investigated?
More recent P021 research has expanded into CDKL5 deficiency. Researchers tested P021 in SH-CDKL5-KO cells and in young and adult Cdkl5 knockout mice. The cell experiments examined neuronal proliferation, survival, and maturation. The mouse experiments examined neuroanatomical and behavioral changes. The results were not the same across the two models.
Another research direction has examined brain microstructure with diffusion MRI. Work in 3xTg-AD mice used diffusion MRI and diffusional kurtosis imaging to detect microstructural changes after early P021 treatment. This adds imaging-based measures to the earlier cellular, molecular, and behavioral research on P021.
How Does the P-21 Evidence Base Differ From Cerebrolysin?
P-21 research remains focused on preclinical studies using cell systems and animal models. The available studies examine biological and behavioral measures under controlled experimental conditions. The P-21 studies reviewed here do not provide an established human clinical evidence base.
Cerebrolysin has a broader research base that includes analytical, preclinical, and human clinical studies. This difference in research scope is why Cerebrolysin provides a useful comparator, while findings from its studies cannot be treated as evidence for P-21.
P-21 vs Cerebrolysin: How Does the Research Differ?
| — Research Characteristic | — P-21 / P021 | — Cerebrolysin |
|---|---|---|
| Research material | Defined synthetic peptidergic compound | Complex peptide preparation |
| Main research base | Primarily preclinical | Analytical, preclinical, and clinical |
| Research models | Transgenic and other animal models | Analytical samples, experimental models, and human clinical populations |
| Molecular measurements | BDNF, GSK3β, tau-related, and amyloid-related measures | Peptide identification and sequence characterization |
| Cellular measures | Neurogenesis and synaptic plasticity | Cellular effects examined in experimental research |
| Behavioral measures | Memory-related and other behavioral testing in animal models | Neurological and functional endpoints in clinical studies |
| Human clinical evidence | Not established by the P021 studies reviewed here | Published randomized clinical studies |
What Are the Main Limitations of P021 Research?
P021 research has important evidence gaps. Most studies use cell systems or animal models, and results can differ between models. For example, work in CDKL5 deficiency found effects in cultured cells that were not fully reproduced in knockout mice. This shows why findings from one experimental model cannot automatically be applied to another.
Another limitation is the limited human evidence. The P021 studies reviewed here remain preclinical. Findings from laboratory and animal research therefore need to remain separate from evidence generated in human clinical studies.
FAQs
References
- Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014 Nov;71:110-30. https://pubmed.ncbi.nlm.nih.gov/25046994/
- Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014 Sep;35(9):2134-46. https://pubmed.ncbi.nlm.nih.gov/24702821/
- Mottolese N, Loi M, Trazzi S, Tassinari M, Uguagliati B, Candini G, Iqbal K, Medici G, Ciani E. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024 Nov 26;16(1):65. https://pubmed.ncbi.nlm.nih.gov/39592934/
- Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH. Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging. 2026 Jun;129:110641. https://pubmed.ncbi.nlm.nih.gov/41740658/
- Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2015;47(3):557-64. https://pubmed.ncbi.nlm.nih.gov/26401692/
- Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016 Jan;47(1):151-9. https://pubmed.ncbi.nlm.nih.gov/26564102/